Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus
出版年份 2017 全文链接
标题
Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus
作者
关键词
-
出版物
POSTGRADUATE MEDICINE
Volume 129, Issue 8, Pages 811-821
出版商
Informa UK Limited
发表日期
2017-07-27
DOI
10.1080/00325481.2017.1358064
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug
- (2017) Hao Wu et al. NATURE MEDICINE
- Metformin and the gastrointestinal tract
- (2016) Laura J. McCreight et al. DIABETOLOGIA
- Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials
- (2016) J. Kongwatcharapong et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A Multicenter Observational Study of Incretin-based Drugs and Heart Failure
- (2016) Kristian B. Filion et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
- (2016) Dimitris Varvaki Rados et al. PLOS MEDICINE
- Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
- (2015) Julio Rosenstock et al. Cardiovascular Diabetology
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
- (2015) Juraj Koska et al. Diabetes & Vascular Disease Research
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
- (2015) B. Bode et al. DIABETES OBESITY & METABOLISM
- Association of Cardiometabolic Multimorbidity With Mortality
- (2015) Emanuele Di Angelantonio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Excess Mortality among Persons with Type 2 Diabetes
- (2015) Mauro Tancredi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Metformin on Metabolic Improvement and Gut Microbiota
- (2014) Heetae Lee et al. APPLIED AND ENVIRONMENTAL MICROBIOLOGY
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- (2014) Raymond V. Oliva et al. Journal of the American Society of Hypertension
- Metformin—mode of action and clinical implications for diabetes and cancer
- (2014) Ida Pernicova et al. Nature Reviews Endocrinology
- Switching α-Glucosidase Inhibitors to Miglitol Reduced Glucose Fluctuations and Circulating Cardiovascular Disease Risk Factors in Type 2 Diabetic Japanese Patients
- (2014) Natsuyo Hariya et al. Drugs in research & development
- Cardiovascular impact of drugs used in the treatment of diabetes
- (2014) Chris R. Triggle et al. Therapeutic Advances in Chronic Disease
- GLP-1 receptor agonists: a review of head-to-head clinical studies
- (2014) Jennifer M. Trujillo et al. Therapeutic Advances in Endocrinology and Metabolism
- Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
- (2013) M. Katout et al. AMERICAN JOURNAL OF HYPERTENSION
- Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors
- (2013) M. Barbieri et al. ATHEROSCLEROSIS
- GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
- (2013) Daniel Lorber Cardiovascular Therapeutics
- Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure
- (2013) Dean T. Eurich et al. Circulation-Heart Failure
- Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis
- (2013) J. E. Schopman et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metformin: an old but still the best treatment for type 2 diabetes
- (2013) Lilian Beatriz Aguayo Rojas et al. Diabetology & Metabolic Syndrome
- DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia
- (2012) Jacob Lønborg et al. Circulation-Cardiovascular Interventions
- Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis
- (2012) K. M. Pantalone et al. DIABETES OBESITY & METABOLISM
- Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
- (2012) D. Nathanson et al. DIABETOLOGIA
- Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity
- (2012) C. Seifarth et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Glimepiride Treatment Facilitates Ischemic Preconditioning in the Diabetic Heart
- (2012) Derek J. Hausenloy et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
- (2011) Robert Ratner et al. Cardiovascular Diabetology
- Cellular and molecular mechanisms of metformin: an overview
- (2011) Benoit Viollet et al. CLINICAL SCIENCE
- The cardioprotective effects of metformin
- (2011) Saloua El Messaoudi et al. CURRENT OPINION IN LIPIDOLOGY
- Treating diabetes today: a matter of selectivity of sulphonylureas
- (2011) S. Seino et al. DIABETES OBESITY & METABOLISM
- Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
- (2011) Tina Ken Schramm et al. EUROPEAN HEART JOURNAL
- Metformin and heart failure: never say never again
- (2011) Nikolaos Papanas et al. EXPERT OPINION ON PHARMACOTHERAPY
- Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community
- (2011) Sotero P. Romero et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Rosiglitazone Revisited
- (2010) Steven E. Nissen et al. ARCHIVES OF INTERNAL MEDICINE
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and Diabetes
- (2009) Digish D. Shah et al. JOURNAL OF CARDIAC FAILURE
- Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy
- (2008) Wolfgang C. Winkelmayer et al. ARCHIVES OF INTERNAL MEDICINE
- Cardiovascular Outcomes in Trials of Oral Diabetes Medications
- (2008) Elizabeth Selvin et al. ARCHIVES OF INTERNAL MEDICINE
- Metabolic syndrome and stroke
- (2008) Amytis Towfighi et al. Current Diabetes Reports
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Paget's Disease of the Mandible
- (2008) Mayank B. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
- (2008) W. Kim et al. PHARMACOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started